Kimyrsa and Orbactiv – A Tale of Two Formulations
Brittany T Jackson,1 David B Cluck,2 Andrés F Henao-Martínez,3 Daniel B Chastain4 1Department of Pharmacy, Mount Sinai Morningside, New York, NY, 10025, USA; 2Department of Pharmacy Practice, Bill Gatton College of Pharmacy East Tennessee State University, Johnson City, TN, 37614, USA; 3Division of...
Main Authors: | Jackson BT, Cluck DB, Henao-Martínez AF, Chastain DB |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2023-03-01
|
Series: | Drug Design, Development and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/kimyrsa-and-orbactiv--a-tale-of-two-formulations-peer-reviewed-fulltext-article-DDDT |
Similar Items
-
Glycopeptide Hypersensitivity and Adverse Reactions
by: Vanthida Huang, et al.
Published: (2020-04-01) -
Glycopeptide Antibiotics: Structural and Functional Aspects, Human Medicinal Use, and Standardisation
by: O. N. Vysochanskaya, et al.
Published: (2023-07-01) -
Real-World Use of Dalbavancin for Treatment of Soft Tissue and Bone Infection in Children: Safe, Effective and Hospital-Time Sparing
by: Désirée Caselli, et al.
Published: (2024-01-01) -
Updated Review on Clinically-Relevant Properties of Delafloxacin
by: Adrien Turban, et al.
Published: (2023-07-01) -
Use of Dalbavancin in Skin, Bone and Joint Infections: A Real-Life Experience in an Italian Center
by: Lucia Brescini, et al.
Published: (2021-09-01)